NeurologyLive® Friday 5 — November 17, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Efficacy and Safety of Weekly Subcutaneous Efgartigimod for Myasthenia Gravis: Yuebing Li, MD, PhD

The neuromuscular neurologist at the Cleveland Clinic discussed findings from an analysis presented at AANEM 2023 that investigated the safety and efficacy of subcutaneous efgartigimod in patients with myasthenia gravis. [WATCH TIME: 5 minutes]

2: Mechanistic Potential of Synapse-Targeted Agent ALX-001 for Alzheimer Disease: Adam Mecca, MD, PhD

The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine discussed the mechanism of action of ALX-001, a highly selective agent in development for neurodegenerative diseases. [WATCH TIME: 5 minutes]

3: NeuroVoices: Susan Landau, PhD, on the POINTER Trial and Understanding the Link Between Elevated Alzheimer Biomarkers and Cognition

In this edition of NeuroVoices, the research neuroscientist at the University of California Berkeley provided insight on findings from the US POINTER study and why previous thoughts on the link between relevant biomarkers and cognition may be slightly incorrect.

4: Improving Care and Education on Rare Neuroimmune Disorders in Spanish-Speaking Communities: Paula Barreras, MD, PhD

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center provided perspective on the patient-clinician relationships and the need to educate clinicians about the impacts of rare neuroimmune disorders in Spanish-speaking communities. [WATCH TIME: 3 minutes]

5: Effects of Long-term CPAP Therapy in Multiple Sclerosis: Daria Trojan, MD, MSc

The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]